-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis Pharma Releases Topline Data From Phase 3 Open-Label Study Of Denifanstat (ASC40), Licensed from Sagimet Biosciences, For Acne Vulgaris

Benzinga·01/29/2026 11:04:48
Listen to the news
  • Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study
  • The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne
  • New Drug Application for denifanstat (ASC40) for acne was recently accepted by the China National Medical Products Administration